Appointment dossier — Ovarian Sarcoma

Compounds studied in Ovarian Sarcoma

• Cyclophosphamide — Human evidence · 0 positive / 1 negative-mixed · PMID 6616409
• Vincristine — Human evidence · 0 positive / 1 negative-mixed · PMID 6616409
• Cisplatin — Animal evidence · 1 positive · PMID 14643924
• Doxorubicin — Animal evidence · 1 positive / 2 negative-mixed · PMID 14643924, 36295661, 11766987

“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.

Open recruiting trials (18)

• NCT03382158 — International PPB/DICER1 Registry (United States)
• NCT05824975 · Phase 1 / Phase 2 — A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) (United States)
• NCT06943521 · Phase 1 / Phase 2 — A Study of MT-4561 in Patients With Various Advanced Solid Tumors (United States)
• NCT07410676 · Phase 1 / Phase 2 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors (China)
• NCT05296564 · Phase 1 / Phase 2 — Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers (Israel)
• NCT05969860 · Phase 2 — At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer (United States)
• NCT04851119 · Phase 1 / Phase 2 — Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors (United States)
• NCT06638931 · Phase 2 — Agnostic Therapy in Rare Solid Tumors (Brazil)
• NCT06760819 · Phase 2 — A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) (United States)
• NCT07341737 · Phase 1 / Phase 2 — SL-28 for Advanced Solid Tumours (Australia)
• NCT07229313 · Phase 1 — A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors (United States)
• NCT07244835 · Phase 1 — A Study of DEG6498 in Participants With Solid Tumors (China)
• NCT05740956 · Phase 1 — A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors (China)
• NCT06687070 · Phase 1 — APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST (China)
• NCT06337084 · Phase 1 — Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors (Australia)
• NCT07544030 · Phase 3 — A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Advanced Epithelial Ovarian Cancer (China)
• NCT06580314 · Phase 3 — Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer (United States)
• NCT07064018 · Phase 1 / Phase 2 — Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies (United States)

Most-relevant first: trials that name Ovarian Sarcoma, then broader trials you may still qualify for. 43 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.

Financial help to look into

• PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
• HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
• CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
• Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
• NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/

For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.

Questions to ask your oncologist

1. I've read that Cyclophosphamide has been studied in people for Ovarian Sarcoma — what's the evidence, and is it an option or available in a trial for me?
2. I've read that Vincristine has been studied in people for Ovarian Sarcoma — what's the evidence, and is it an option or available in a trial for me?
3. Of the open trials I found (for example NCT03382158), am I eligible for any — here or at a larger cancer center?
4. What is my exact diagnosis — the type, subtype, stage, and grade?
5. Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
6. Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
7. What is the goal of treatment for me — cure, long-term control, or comfort?
8. What are all of my standard treatment options, and what does each one involve?
9. What is the realistic benefit of each option, in actual numbers?
10. What are the most common and the most serious side effects, and how are they managed?
11. How will we know if treatment is working, and how often will I be scanned or tested?
12. If the first treatment doesn't work, what are the next options?
13. Are there gentler options if I want to prioritize quality of life?
14. Am I eligible for any clinical trials — here or at a larger/academic cancer center?
15. Is my case reviewed by a multidisciplinary tumor board?
16. Would a second opinion at a center that treats my cancer often be worthwhile?
17. Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
18. Which symptoms are emergencies, and who do I call after hours?
19. Should I see palliative or supportive care alongside my treatment?
20. How will treatment affect my daily life, work, and (if it matters to me) fertility?
21. What can I safely do myself — diet and activity — and is anything I'm taking risky?
22. What will treatment cost, and is financial assistance available?